It can also reduce the production of several pro-inflammatory cytokines and pro-angiogenic growth factors in human breast cancer cells31; and enhance the therapeutic efficacy of TRAIL in a prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis32. Here, TNFSF10 is linked to prostate carcinoma.